Latest Publications

Featured Article

Blood Advances. 09/07/2019

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study

Allison Barraclough, Musa Alzahrani, Marianne Schmidt Ettrup, Mark Bishton, Chris van Vliet, Pedro Farinha, Clare Gould, Simone Birch, Laurie H. Sehn, Vishakha Sovani, Mitchell Steven Ward, Bradley Augustson, Jorne Biccler, Joseph M. Connors, David W. Scott, Maher K. Gandhi, Kerry J. Savage, Tarec El-Galaly, Diego Villa and Chan Yoon Cheah

Link to online journal article

---

211 patients were identified for this retrospective study across Sir Charles Gairdner Hospital, Hollywood Private Hospital, Princess Alexandra Hospital, British Columbia Centre for Lymphoid Cancer, Aalborg University Hospital, and Nottingham University Hospital.

Key points of note:

- In early-stage DLBCL, COO and DE/DH [gene expression] status may not confer an inferior prognosis.
- Stage I/II DLBCL has an excellent outcome when treated with R-CHOP–like therapy ± radiation, with 4-year Progression Free Survival and Overall Survival rates of 85% and 88%.

More Publications

• Peripheral T-Cell Lymphoma Arising in Patients With Chronic Lymphocytic Leukemia.
  Source: Dr Chan CheahPublished on 2019-08-22
• Peripheral T-Cell Lymphoma Arising in Patients With Chronic Lymphocytic Leukemia.
  Source: Dr David JoskePublished on 2019-08-22
• Peripheral T-Cell Lymphoma Arising in Patients With Chronic Lymphocytic Leukemia.
  Source: Dr Dejan RadeskiPublished on 2019-08-22
• Platelets in myeloproliferative neoplasms have a distinct transcript signature in the presence of marrow fibrosis.
  Source: Dr Carolyn GrovePublished on 2019-08-20
• Platelets in myeloproliferative neoplasms have a distinct transcript signature in the presence of marrow fibrosis.
  Source: Dr Rebecca HowmanPublished on 2019-08-20
• Refractory α/β-Hepatosplenic T-cell Lymphoma With Secondary CNS Dissemination and Severe Morbidity Related to Intrathecal Chemotherapy: A Case Report and Literature Review.
  Source: Dr Chan CheahPublished on 2019-08-01
• Refractory α/β-Hepatosplenic T-cell Lymphoma With Secondary CNS Dissemination and Severe Morbidity Related to Intrathecal Chemotherapy: A Case Report and Literature Review.
  Source: Dr Dejan RadeskiPublished on 2019-08-01
• Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
  Source: Dr Gavin CullPublished on 2019-07-26
• Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of ‘real-world’ experience from Western Australia.
  Source: Dr David JoskePublished on 2019-07-16
• Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of ‘real-world’ experience from Western Australia.
  Source: Dr Gavin CullPublished on 2019-07-16
• Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of ‘real-world’ experience from Western Australia.
  Source: Dr Dejan RadeskiPublished on 2019-07-16
• COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.
  Source: Dr Chan CheahPublished on 2019-07-10
• COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.
  Source: Dr Bradley AugustsonPublished on 2019-07-10
• Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance.
  Source: Dr Chan CheahPublished on 2019-07-02
• Care After Lymphoma (CALy) trial: A phase II pilot pragmatic randomised controlled trial of a nurse-led model of survivorship care.
  Source: Dr David JoskePublished on 2019-06-24

Older posts